D68.022
BillableVon Willebrand disease, type 2M
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D68.022 an HCC code?
Yes. D68.022 maps to Von Willebrand Disease and Other Coagulation Defects under the CMS-HCC V28 risk adjustment model (and Coagulation Defects and Other Specified Hematological Disorders under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D68.022
For D68.022 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D68.022 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D68.022 is the ICD-10-CM diagnosis code for von willebrand disease, type 2m. A bleeding disorder caused by abnormal von Willebrand factor protein (type 2M), affecting blood clotting through reduced platelet binding. D68.022 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering coagulation defects, purpura and other hemorrhagic conditions (d65-d69).
Under the CMS-HCC V28 risk adjustment model, D68.022 maps to Von Willebrand Disease and Other Coagulation Defects (HCC 112) with a community, non-dual, aged base RAF weight of 0.247. Under the older CMS-HCC V24 model, D68.022 maps to Coagulation Defects and Other Specified Hematological Disorders (HCC 48) with a community, non-dual, aged base RAF weight of 0.209. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Confirm type 2M diagnosis is explicitly stated in documentation; this type involves defective platelet-binding function. Because D68.022 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D68.022 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Confirm type 2M diagnosis is explicitly stated in documentation; this type involves defective platelet-binding function
- •Link to relevant lab findings such as reduced ristocetin cofactor activity to justify the specific type classification
Clinical Significance
Von Willebrand disease type 2M is characterized by decreased VWF-dependent platelet adhesion with a normal VWF multimer pattern, distinguishing it from Type 2A. The qualitative defect reduces VWF's ability to bind platelets despite producing normal-sized multimers. Patients typically present with moderate mucocutaneous bleeding.
Documentation Requirements
- ✓Document VWF activity disproportionately reduced compared to VWF antigen (low activity-to-antigen ratio), normal multimer distribution on analysis, and factor VIII levels.
- ✓Record genetic mutation data if available and DDAVP response testing, as some Type 2M patients may respond to desmopressin.